
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson's recent financial performance reflects a positive trajectory, with the Medical segment (MMS) achieving sales of $888 million in FQ3'25, marking a year-over-year growth of 5.3%, driven by robust demand in Infusion Systems and Dispensing Solutions. The company's MedTech business has consistently grown at a rate exceeding 6% annually since the launch of the BD 2025 initiative, accompanied by improving margins. Additionally, the MDS segment reported FY24 sales of $4.43 billion, reflecting a year-over-year increase of 3.2%, further solidifying the company’s strong position in the healthcare market.
Bears say
Becton Dickinson's organic revenue growth outlook has been downgraded from an initial projection of 4.0-4.5% to a range of 3.0-3.5%, indicating a more pessimistic view of future performance. In the most recent financial quarter (FQ3'25), the company reported a 1.1% year-over-year decline in sales, highlighting persistent weaknesses in key segments such as Biosciences and Diagnostic Solutions, which were further exacerbated by external pressures in China. Additionally, challenges such as reduced government research grants and slow recovery in key testing areas are expected to impose substantial growth headwinds moving forward.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares